Abelacimab has shown better safety than rivaroxaban in atrial fibrillation patients
A recent study reveals that abelacimab reduces the rate of bleeding events significantly more than rivaroxaban in atrial fibrillation patients, thereby providing a safer alternative for anticoagulation. A novel Factor XI inhibitor called abelacimab reduced significantly the events of bleed in patients with atrial fibrillation relative to the most commonly used anticoagulant, rivaroxaban, showed a…